SQZ Biotechnologies
Cell therapy company developing treatments by engineering immune cells using its proprietary Cell Squeeze technology platform, which mechanically deforms cells to enable intracellular delivery of therapeutic payloads. Publicly traded on NYSE (SQZ).
Notes
SQZ Biotechnologies is a cell therapy company developing treatments by engineering immune cells using its proprietary Cell Squeeze technology platform. The company is publicly traded on NYSE under the ticker symbol SQZ and is headquartered in Watertown, Massachusetts.
The Cell Squeeze technology works by passing cells through microfluidic channels that mechanically deform the cell membrane, creating temporary pores that allow therapeutic payloads (proteins, nucleic acids, etc.) to enter the cell. This approach offers several advantages:
- Rapid, scalable cell engineering
- Ability to deliver a wide range of cargo types
- Preservation of cell viability and function
- Potential for point-of-care manufacturing
SQZ is developing cell therapies for oncology, infectious diseases, and immune tolerance applications.
Team
- Howard Bernstein, M.D., Ph.D. - Co-founder & Chief Scientific Officer
- Armon Sharei, Ph.D. - Co-founder (MIT spinout)
Additional Research Findings
- NYSE: SQZ (publicly traded)
- Portfolio company of Polaris Partners
- Cell Squeeze microfluidic technology platform
- MIT spinout company
- Applications in oncology, infectious disease, immune tolerance
- Watertown, Massachusetts headquarters
- Founded in 2013
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Polaris Partners | US | biotech-focused | - | 33 |